International Clinical Psychopharmacology最新文献_第9页

Does the comorbidity of borderline personality disorder affect the response to treatment in bipolar patients? 边缘型人格障碍是否会影响双相情感障碍患者对治疗的反应？

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-07-04 DOI: 10.1097/YIC.0000000000000489

Cecilia Maria Esposito, Jennifer L Barkin, Alessandro Ceresa, Massimiliano Buoli

{"title":"Does the comorbidity of borderline personality disorder affect the response to treatment in bipolar patients?","authors":"Cecilia Maria Esposito, Jennifer L Barkin, Alessandro Ceresa, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000489","DOIUrl":"10.1097/YIC.0000000000000489","url":null,"abstract":"Bipolar disorder (BD) is a highly prevalent condition whose response to pharmacological treatment is associated with a number of factors including psychiatric comorbidity. Borderline personality disorder (BPD) shares clinical symptoms and biological vulnerability with BD and the two conditions are frequently comorbid, thus representing a clinical challenge. The purpose of the present review is to summarize the data related to treatment response in bipolar patients with comorbid BPD. According to systematic review process, a literature search was performed on the PubMed, Embase, PsycInfo, Isi Web of Knowledge, Medscape, and Cochrane Library databases. Peer-reviewed articles until December 2022 were eligible for inclusion. Comorbidity with BPD seems to be associated with a more difficult clinical stabilization in bipolar patients, often requiring poly-therapy or a longer duration of hospitalization. However, three studies, assessing the effectiveness of mood stabilizers in bipolar patients, did not demonstrate a prominent influence of BPD comorbidity in achieving clinical response. The most frequently administered pharmacological treatments in the selected studies include mood stabilizers and atypical antipsychotics. The presence of comorbid BPD in bipolar patients may hamper treatment effectiveness. Future studies, comparing different treatments and with larger samples, are needed to confirm the results critically summarized in the present review.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"51-58"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective, comparative, pilot study of maintenance treatment in comorbid bipolar disorders with post-traumatic stress disorder. 对合并有创伤后应激障碍的双相情感障碍患者进行维持治疗的前瞻性比较试验研究。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-22 DOI: 10.1097/yic.0000000000000543

Hernán F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-Lopez, Angela T H Kwan, Roger S McIntyre

{"title":"Prospective, comparative, pilot study of maintenance treatment in comorbid bipolar disorders with post-traumatic stress disorder.","authors":"Hernán F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-Lopez, Angela T H Kwan, Roger S McIntyre","doi":"10.1097/yic.0000000000000543","DOIUrl":"https://doi.org/10.1097/yic.0000000000000543","url":null,"abstract":"There is limited real-world evidence that evaluates the impact of monotherapy vs. combination therapy as a maintenance treatment in comorbid post-traumatic stress disorder (PTSD) in bipolar disorder (BD). Our aim was to compare lithium vs. lithium plus quetiapine in maintenance treatment in a sample of comorbid BD with PTSD. An exploratory, comparative pilot study over a 28-week period in 34 comorbid BD with PTSD patients was performed to compare monotherapy (n = 18) vs. combination therapy (n = 16) during maintenance treatment. The primary outcome was the time to event of recurrence of any mood episode. The secondary outcomes were regarding change from the baseline to endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS). A Cox regression, Kaplan-Meir survival, and mixed-effects model for repeated measures analyses were performed. Lithium plus quetiapine reduces the risk of recurrence of any mood episode. There are significant differences between baseline and endpoint for YMRS, MADRS, and CGI-BP scales in the sample. In this pilot, exploratory analysis, combination therapy during maintenance treatment for comorbid BD with PTSD may be effective in preventing recurrences of any type of mood episode.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"47 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139920310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors. 微粉化/超微粉化棕榈酰乙醇酰胺可改善2019年冠状病毒病（COVID-19）幸存者的抑郁和疲劳。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-22 DOI: 10.1097/yic.0000000000000537

Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini

{"title":"Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors.","authors":"Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini","doi":"10.1097/yic.0000000000000537","DOIUrl":"https://doi.org/10.1097/yic.0000000000000537","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months. Those accepting m/umPEA therapy (n = 57) were compared with those who did not (n = 41), in terms of depression, fatigue, chronic pain and subjective well-being, through validated scales administered pre- and posttreatment. The two groups did not differ in terms of demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID-19 severity and baseline neuropsychiatric status. Patients receiving m/umPEA showed a greater improvement in depression and fatigue (both P < 0.05). Conversely, no association was found with changes in chronic pain or subjective well-being. At multivariable logistic regression, m/umPEA predicted neuropsychiatric improvement independently of age, sex and baseline neuropsychiatric status. Worse pretreatment fatigue and subjective well-being identified those who most likely benefited from treatment. In conclusion, despite its retrospective nature, our study suggests that m/umPEA may improve depression and fatigue in COVID-19 survivors, justifying future research in this setting.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"6 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139920115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the influence of nonproblematic alcohol intake on the outcome of major depression. 评估非问题性酒精摄入对重度抑郁症结果的影响。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-22 DOI: 10.1097/yic.0000000000000545

Víctor Navarro, Joana Guarch, Ilham Boulahfa, Laia Tardón, Amadeu Obach, Cristóbal Gastó, Manel Vila-Vidal

{"title":"Evaluating the influence of nonproblematic alcohol intake on the outcome of major depression.","authors":"Víctor Navarro, Joana Guarch, Ilham Boulahfa, Laia Tardón, Amadeu Obach, Cristóbal Gastó, Manel Vila-Vidal","doi":"10.1097/yic.0000000000000545","DOIUrl":"https://doi.org/10.1097/yic.0000000000000545","url":null,"abstract":"The effect of light or moderate alcohol intake on the outcome of patients with major depression taking antidepressants is a question that remains unanswered. The main objective of this study was to assess the association between light or moderate alcohol consumption and the acute response (efficacy and tolerability) to pharmacological treatment in unipolar major depression. Efficacy and tolerability analyses compared 8-week outcomes between three subgroups, abstainers, light drinkers and moderate drinkers, of patients with major depression using a prospective naturalistic single-blind design. The treatment strategy was adapted from a local clinical guideline. Antidepressants prescribed were escitalopram, venlafaxine extended-release and imipramine; benzodiazepines and antipsychotics could be prescribed as needed. The final sample consisted of 614 severe unipolar major depressive inpatients and outpatients aged 18 years or older. Notably, no significant differences in efficacy or tolerability (including all subscores assessed) were found between the abstainer and nonproblematic drinker subgroups. Without ever forgetting the serious implicit risks associated with the inappropriate use of alcohol, in conclusion, our results suggest that nonproblematic alcohol consumption does not influence the outcome of patients diagnosed with an acute severe major depressive episode.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"43 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139920055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders. 精神分裂症、情感分裂症和双相情感障碍患者的代谢综合征及其与抗精神病药物多药治疗的关系。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-13 DOI: 10.1097/yic.0000000000000538

Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry

{"title":"Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.","authors":"Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry","doi":"10.1097/yic.0000000000000538","DOIUrl":"https://doi.org/10.1097/yic.0000000000000538","url":null,"abstract":"The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and polypharmacy. We conducted a cross-sectional study on patients seen between January 2017 and December 2020, collecting data on the class, type, route of administration and number of antipsychotics received. We used the American Association of Clinical Endocrinology criteria to diagnose MetS. We included 833 subjects of whom 573 (68.8%) received antipsychotic monotherapy and 260 (31.2%) received polypharmacy. Overall, 28.6% (N = 238) had MetS with no statistical difference between the two groups. Diastolic blood pressure and receiving olanzapine were significant predictors for developing MetS. In conclusion, our study found no significant difference in the rate of MetS between antipsychotic monotherapy and polypharmacy. A number of variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for careful choice of antipsychotics and regular screening and management of abnormal metabolic parameters.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"12 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139920190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response? 抗抑郁药与肠道微生物群之间的双向作用：对治疗反应有影响吗？

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-06 DOI: 10.1097/YIC.0000000000000533

Gianluca Borgiani, Chiara Possidente, Chiara Fabbri, Vincenzo Oliva, Mirjam Bloemendaal, Alejandro Arias Vasquez, Ted G Dinan, Eduard Vieta, Marco Menchetti, Diana De Ronchi, Alessandro Serretti, Giuseppe Fanelli

{"title":"The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?","authors":"Gianluca Borgiani, Chiara Possidente, Chiara Fabbri, Vincenzo Oliva, Mirjam Bloemendaal, Alejandro Arias Vasquez, Ted G Dinan, Eduard Vieta, Marco Menchetti, Diana De Ronchi, Alessandro Serretti, Giuseppe Fanelli","doi":"10.1097/YIC.0000000000000533","DOIUrl":"10.1097/YIC.0000000000000533","url":null,"abstract":"This review synthesizes the evidence on associations between antidepressant use and gut microbiota composition and function, exploring the microbiota's possible role in modulating antidepressant treatment outcomes. Antidepressants exert an influence on measures of gut microbial diversity. The most consistently reported differences were in β-diversity between those exposed to antidepressants and those not exposed, with longitudinal studies supporting a potential causal association. Compositional alterations in antidepressant users include an increase in the Bacteroidetes phylum, Christensenellaceae family, and Bacteroides and Clostridium genera, while a decrease was found in the Firmicutes phylum, Ruminococcaceae family, and Ruminococcus genus. In addition, antidepressants attenuate gut microbial differences between depressed and healthy individuals, modulate microbial serotonin transport, and influence microbiota's metabolic functions. These include lyxose degradation, peptidoglycan maturation, membrane transport, and methylerythritol phosphate pathways, alongside gamma-aminobutyric acid metabolism. Importantly, baseline increased α-diversity and abundance of the Roseburia and Faecalibacterium genera, in the Firmicutes phylum, are associated with antidepressant response, emerging as promising biomarkers. This review highlights the potential for gut microbiota as a predictor of treatment response and emphasizes the need for further research to elucidate the mechanisms underlying antidepressant-microbiota interactions. More homogeneous studies and standardized techniques are required to confirm these initial findings.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

No gender differences in the pharmacological emergency treatment of schizophrenia: results of a 21-year observation. 精神分裂症的药物急救治疗无性别差异:一项21年观察的结果

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000495

Monika Edlinger, Stefanie Brettbacher, Timo Schurr, Nursen Yalcin-Siedentopf, Alex Hofer

{"title":"No gender differences in the pharmacological emergency treatment of schizophrenia: results of a 21-year observation.","authors":"Monika Edlinger, Stefanie Brettbacher, Timo Schurr, Nursen Yalcin-Siedentopf, Alex Hofer","doi":"10.1097/YIC.0000000000000495","DOIUrl":"10.1097/YIC.0000000000000495","url":null,"abstract":"Patients suffering from schizophrenia are at high risk for admission and treatment in locked units. This study investigated gender differences in the pharmacological emergency treatment of schizophrenia patients over a 21-year observation period. The current retrospective study was conducted at the Division of Psychiatry I of the Medical University Innsbruck. All adult patients (n = 845; 425 female) suffering from schizophrenia who were admitted involuntarily to one of the acute psychiatric units in the years 1997, 2002, 2007, 2012 and 2017 were included in the study. In the years mentioned above, 590 schizophrenia patients (297 men, 293 women) admitted to a locked unit received pharmacological emergency treatment. With the exception of clozapine which was more frequently administered to men no significant differences between men and women were found in terms of the choice, dosage, and type of application of medication (antipsychotics and benzodiazepines). Since most treatment guidelines for schizophrenia do not consider gender differences at all, it is not surprising that acute treatment is almost the same for men and women. However, in times when individualized therapies gain more and more importance, the consideration of sex differences should be part of new treatment concepts.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"36-41"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10316876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia. 女性精神分裂症患者抗精神病药物引起的闭经可能的遗传生物标志物。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000501

Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, Jung-Mee Ahn, Do-Un Jung, Dong-Jin Kim, Hye-Eun Jeong, Eun-Young Kim, Dong-Wook Jeon, Sung-Jin Kim, Jae-Gook Shin

{"title":"Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia.","authors":"Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, Jung-Mee Ahn, Do-Un Jung, Dong-Jin Kim, Hye-Eun Jeong, Eun-Young Kim, Dong-Wook Jeon, Sung-Jin Kim, Jae-Gook Shin","doi":"10.1097/YIC.0000000000000501","DOIUrl":"10.1097/YIC.0000000000000501","url":null,"abstract":"This study explored the association of pharmacogenomics with antipsychotic-induced amenorrhea in female patients with schizophrenia. A total of 89 female schizophrenia patients aged 18-40 receiving consistent antipsychotics at a consistent dose for more than 3 months were enrolled in this study. Amenorrhea was defined as the absence of menstrual period for 3 months or three periods in a row. Serum levels of prolactin, estradiol, follicle-stimulating hormone, luteinizing hormone, and thyroid-stimulating hormone were measured and Cytochrome P450 2D6, dopamine receptor D2 ( DRD2 ) and estrogen receptor 1 were genotyped. Twenty-two patients with amenorrhea had higher prolactin levels and lower estradiol levels than those without amenorrhea (94.1 vs. 71.5 ng/ml for prolactin; P = 0.044 and 27.0 vs. 46.7 pg/ml for estradiol; P = 0.007, respectively). Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.01-4.17; P = 0.049] and drugs increasing prolactin levels (OR = 6.17, 95% CI = 1.28-29.64; P = 0.023) as significant covariates for antipsychotic-induced amenorrhea. This study suggests that DRD2 -141C deletion is associated with antipsychotic-induced amenorrhea although further studies are needed.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"29-35"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9945361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Microsampling for therapeutic drug monitoring in psychiatric practice. 精神病学实践中治疗药物监测的显微取样。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-16 DOI: 10.1097/YIC.0000000000000503

Michele Protti, Roberto Mandrioli, Laura Mercolini

引用次数: 1

Focus on antipsychotics and related therapeutic drug monitoring. 专注于抗精神病药物及相关治疗药物的监测。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-11-19 DOI: 10.1097/YIC.0000000000000523

Alessandro Serretti

引用次数: 0